NanoViricides Advances MPox Treatment NV-387 into Phase II Clinical Trials
TL;DR
NanoViricides Inc. is nearing finalization of its Phase II trial for NV-387, potentially offering a first-mover advantage in treating MPox and smallpox with a novel oral gummy formulation.
NanoViricides Inc.'s two-part Phase II trial in the DRC will evaluate NV-387's safety, dosing, and efficacy against MPox Clade Ia and Ib, targeting 80 patients with oral lesions.
NV-387's development by NanoViricides Inc. could significantly improve global health by providing an effective treatment for MPox and smallpox, reducing suffering and epidemic risks.
NanoViricides Inc. is testing NV-387 oral gummies for MPox, a creative solution to ease administration for patients with painful oral lesions, marking a potential breakthrough in antiviral therapy.
Found this article helpful?
Share it with your network and spread the knowledge!
NanoViricides, Inc. (NYSE American: NNVC), a leader in the development of broad-spectrum antiviral therapies, has announced the near-finalization of its adaptive clinical trial protocol for NV-387, its innovative drug candidate targeting MPox Clade Ia and Ib. This development marks a significant step forward in the fight against orthopoxviruses, with NV-387 poised to become the first drug demonstrating clinical efficacy against such viruses in humans.
The Phase II trial, designed to enroll approximately 80 patients in the Democratic Republic of Congo, will evaluate the safety, dosing, and efficacy of NV-387 oral gummies. This formulation is specifically designed to facilitate administration for patients suffering from painful oral lesions, a common symptom of MPox. The trial's adaptive design allows for modifications based on interim results, potentially accelerating the path to regulatory approval.
Current treatments for MPox, such as Tecovirimat and Brincidofovir, have been hampered by limited efficacy and adverse effects in clinical trials. NV-387's development addresses these shortcomings, offering hope for a more effective and safer alternative. Success in these trials could lead NanoViricides to seek regulatory approvals across Africa, the United States, and globally, including for the treatment of smallpox, underscoring the drug's broad potential impact.
The urgency of this development is highlighted by the ongoing threat posed by Clade 1b MPox in Africa, which remains a transmissible epidemic risk with potential implications for Western nations. The advancement of NV-387 into Phase II trials represents a critical milestone in global health security, offering a promising tool in the containment and treatment of MPox and related orthopoxviruses.
For more information on NanoViricides and its groundbreaking work in antiviral therapy, visit https://www.NanoViricides.com.
Curated from InvestorBrandNetwork (IBN)
